Share Price, page-6

There is no commitment to fda Q1CY. Every chance it needs more studies if they take one path and the other avenue doesn’t provide any more market advantage than apple or Garmin have already got. Plus MEB has no device and no diagnostic lgorithm. Just support tracking which will never be picked up by GPs.

Dave is good, I’m sure. But here’s what bothers me. 

Chris clearly did a deal with the board and instos to step down in return for 249 support so he could preserve his dignity in other board positions. They agreed to fund in return only to get hope to begrudgingly mitigate their losses and not because they are excited about it. 

Claude is no value add as a board position. He was given shares in the Bioprospect days and hasn’t bought a single $

if his own shares since. They needed and Australian and no one else if more would step into the risk. 

There is every chance the raise will be spent on legal fees. Either Pursuing Khouri group for partly paids, or Khouri group suing MEB for mismanagement and false promises, or Cosentino or a class action. All these groups would have held off til MEB had funds. 

There is is still no “algorithm” for diagnosis which is what we all signed on for. 

There is no one on Board or Exec with an iota of mental health experience other than Dr Prendergast. 

A multitude of companies have  recently launched in this space 

and MEB are still relying on data banks that were not as accurate as these companies have now. 

DSM - are changing their diagnostic classifications so there is not a pure depression focus. 

The CMO is not clear whether opioids, VA or eating disorders are likely grant options. 

Anyone seeking to invest should get specific answers to the revenue timeline of a product that is now going to compete with major wearables.